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ABBREVIATIONS: 43 
BCC – basal cell carcinoma 44 
SCC – squamous cell carcinoma 45 
KC – keratinocyte cancer 46 
OC – oral contraceptive 47 
MHT – menopausal hormone therapy 48 
HR – hazard ratio 49 
 50 
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Dear Editor, 53 
Previous research suggests that hormonal factors might influence the development of 54 
keratinocyte cancers (KCs), but the evidence is inconsistent.1, 2 A potential mechanism for an 55 
association is photosensitization via estrogen.3 We examined the association between 56 
hormonal and reproductive factors and subsequent risk of first histologically confirmed 57 
primary BCC or SCC in a large cohort of women that was well-characterized with respect to 58 
important potential confounding factors, as well as clinical factors that may inform about 59 
possible detection bias.  60 
 61 
White women from the QSkin Sun and Health study4 with no past history of melanoma, 62 
excisions for skin cancer or more than 5 self-reported ablations for ‘sunspots or skin cancers’ 63 
were eligible for study (n=11,152). The latter criterion was stipulated to minimize potential 64 
bias caused by including women with prior disease in the analyses, since KCs can be ablated 65 
without a histologically confirmed diagnosis. Information on hormonal and reproductive 66 
factors was self-reported at baseline (2011). KC outcomes were identified from 67 
administrative medical claims data (Medicare - Australia’s universal health insurance 68 
scheme) to June 30, 2014 and exact diagnoses of BCC and SCC established through linkage 69 
with pathology records.5 We used Cox proportional hazards models to estimate the hazard 70 
ratios (HR) associated with OCs and MHT, age at menarche, menopausal status, age at 71 
menopause and parity and first histologically confirmed BCC/SCC, while taking account of 72 
the effects of age, sun exposure, phenotypic and lifestyle characteristics.  73 
 74 
Selected characteristics of the study cohort, overall and amongst post-menopausal women 75 
stratified by MHT use, are provided in Supplementary Table 1. During a median follow-up of 76 
3 years, 336 women developed one or more BCCs (mean age 55.0 years) and 85 women one 77 
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or more SCCs (mean age 55.6 years). We found no association between OC use (ever/never; 78 
duration of use), parity, age at menarche or menopause and incidence of BCC or SCC (Tables 79 
I, II). Among post-menopausal women, ever (vs. never) use of MHT at baseline was 80 
associated with an increased risk of BCC (adjusted HR 1.46; 95%CI 1.07-1.97), but there was 81 
no dose-response with duration of use (P trend 0.2; Table I). MHT use was not associated 82 
with SCC (0.79; 0.45-1.38). We investigated detection bias as a possible explanation for the 83 
positive association between MHT use and BCC through analyses stratified by self-reported 84 
history of skin checks by a doctor, and number of Medicare claims for doctor consultations, 85 
biopsies and cryotherapy treatments during follow-up; we observed no material difference in 86 
the effect estimates according to these factors. The association between MHT use and BCC 87 
did not differ materially across strata of sun exposure variables (data not shown). 88 
 89 
Our findings in relation to both OC and MHT use and BCC accord with findings from two 90 
other prospective studies, the USRT1 and the Danish Diet, Cancer and Health cohort,2 91 
although a significant trend with duration of MHT use was observed in the USRT cohort. A 92 
limitation of our study was the relatively short follow up, and the analyses for SCC were 93 
constrained by sample size.  94 
 95 
In summary, we did not observe an association between OC use or reproductive factors and 96 
incidence of BCC or SCC but found a modest positive association between ever use of MHT 97 
and BCC only. While we found no conclusive evidence of detection bias or confounding to 98 
explain the latter finding, in view of the lack of a dose-response relationship, we counsel 99 
cautious interpretation until further longitudinal studies have explored these associations. 100 
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Table I. Hormonal and reproductive factors and risk of BCC among 11,152 women in the QSkin study cohort. 
 
Variables 
Number of women without 
BCC (n=10,650) 
N (%)
a
 
Number of women with 
BCC (n=336)  
N (%)
a
 
Adjusted
b
 HR (95%CI) P trend
a
 
Age at menarche      
   ≤12 3947 (37.2) 129 (38.7) 1.00 (Ref)  
   13 3184 (30.0) 94 (28.2) 0.84 (0.63-1.11)  
   14 1939 (18.3) 63 (18.9) 0.96 (0.70-1.30)  
   15+ 1538 (14.5) 47 (14.1) 0.91 (0.65-1.29) 0.7 
Parity      
   0 1347 (12.8) 40 (12.0) 1.00 (Ref)  
   1-2 5219 (49.5) 145 (43.7) 0.93 (0.65-1.32)  
   3+ 3989 (37.8) 147 (44.3) 1.15 (0.80-1.64) 0.4 
Menopausal status at baseline      
   Pre-menopausal 4265 (40.2) 122 (36.5) 1.00 (Ref)  
   Post-menopausal 6358 (59.9) 212 (63.5) 0.90 (0.64-1.28)  
OC use (ever never)      
   No 1271 (12.0) 41 (12.3) 1.00 (Ref)  
   Yes 9336 (88.0) 293 (87.7) 1.06 (0.73-1.54)  
Duration of OC use (months)      
   0-6 1271 (12.2) 41 (12.6) 1.00 (Ref)  
   7-60 2486 (23.8) 82 (25.2) 1.11 (0.73-1.68)  
   61-120 2401 (23.0) 73 (22.5) 1.02 (0.66-1.56)  
   121-240 2841 (27.2) 95 (29.2) 1.12 (0.74-1.69)  
   241+ 1437 (13.8) 34 (10.5) 0.83 (0.51-1.37) 0.9 
POST-MENOPAUSAL WOMEN ONLY:     
Age at menopause      
   ≤46 1526 (26.4) 46 (23.1) 1.00 (Ref)  
   47-50 2024 (35.0) 69 (34.7) 1.07 (0.72-1.57)  
   51-52 894 (15.4) 34 (17.1) 1.27 (0.81-2.00)  
   53+ 1346 (23.3) 50 (25.1) 1.05 (0.69-1.62) 0.9 
Table continued 
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Variables 
Number of women without 
BCC (n=10,650) 
N (%)
a
 
Number of women with 
BCC (n=336)  
N (%)
a
 
Adjusted
b
 HR (95%CI) P trend
a
 
MHT use (ever never)      
   No 4079 (65.4) 114 (55.1) 1.00 (Ref)  
   Yes 2162 (34.6) 93 (44.9) 1.46 (1.07-1.97)  
Duration of MHT use (months)      
   0-6 4079 (66.2) 114 (56.7) 1.00 (Ref)  
   7-26 548 (8.9) 24 (11.9) 1.52 (0.96-2.43)  
   27-60 589 (9.6) 24 (11.4) 1.38 (0.87-2.21)  
   61-120 513 (8.3) 21 (10.5) 1.25 (0.73-2.15)  
   121+ 436 (7.1) 19 (9.5) 1.58 (0.93-2.69) 0.2 
MHT use by type of menopause     
Natural menopause - MHT use (ever/never)     
   No 2926 (75.4) 85 (67.5) 1.00 (Ref)  
   Yes 955 (24.6) 41 (32.5) 1.52 (1.01-2.29)  
Hysterectomy – MHT use (ever/never)     
   No 820 (49.7) 21 (38.9) 1.00 (Ref)  
   Yes 831 (50.3) 33 (66.1) 1.26 (0.68-2.33)  
     
a
 Numbers may not sum to total due to missing data; P trend is based on the continuous variable 
b
 Age at menarche adjusted for age at baseline, skin phototype (tanning), freckling on face at age 21, moles at age 21, skin checks by a doctor in the past 3 years and smoking status. 
Parity adjusted for age at baseline, skin color, freckling on face at age 21, moles at age 21 and smoking status. 
Menopausal status at baseline adjusted for age at baseline, skin color, freckling on face at age 21, moles at age 21, skin checks by a doctor in the past 3 years and smoking status. 
Age at menopause adjusted for age at baseline, skin phototype (tanning) and moles at age 21, skin checks by a doctor in the past 3 years and smoking status.  
OC use adjusted for age at baseline, skin color, freckling on face at age 21, moles at age 21, number of sunburns as a child, skin checks by a doctor in the past 3 years and smoking status. 
MHT use adjusted for age at baseline, eye color, moles at age 21, sunburns as a teenager/youth, skin checks by a doctor in the past 3 years and smoking status. 
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Table II. Hormonal and reproductive factors and risk of SCC among 11,152 women in the QSkin study cohort. 
 
Variables 
Number of women without 
SCC (n=10,901) 
N (%)
a
 
Number of women with 
SCC (n=85)  
N (%)
a
 
Adjusted
b
 HR (95%CI) P trend
a
 
Age at menarche      
   ≤12 4037 (37.2) 39 (45.9) 1.00 (Ref)  
   13 3258 (30.0) 20 (23.5) 0.63 (0.37-1.10)  
   14 1985 (18.3) 17 (20.0) 0.82 (0.46-1.47)  
   15+ 1576 (14.5) 9 (10.6) 0.53 (0.25-1.14) 0.2 
Parity      
   0 1381 (12.8) 6 (7.3) 1.00 (Ref)  
   1-2 5320 (49.2) 44 (53.7) 1.63 (0.69-3.85)  
   3+ 4104 (38.0) 32 (39.0) 1.50 (0.62-3.61) 0.4 
Menopausal status at baseline      
   Pre-menopausal 4371 (40.2) 16 (18.8) 1.00 (Ref)  
   Post-menopausal 6501 (59.8) 69 (81.2) 1.26 (0.58-2. 72)  
OC use (ever never)      
   No 1302 (12.0) 10 (11.8) 1.00 (Ref)  
   Yes 9550 (88.0) 75 (88.2) 1.78 (0.81-3.91)  
Duration of OC use (months)      
   0-6 1302 (12.2) 10 (11.9) 1.00 (Ref)  
   7-60 2545 (23.8) 23 (27.4) 1.89 (0.81-4.45)  
   61-120 2454 (23.0) 20 (23.8) 1.89 (0.79-4.53)  
   121-240 2913 (27.3) 23 (27.4) 1.75 (0.73-4.20)  
   241+ 1463 (13.7) 8 (9.5) 1.43 (0.51-4.00) 0.8 
POST-MENOPAUSAL WOMEN ONLY:     
Age at menopause      
   ≤46 1559 (26.3) 13 (21.7) 1.00 (Ref)  
   47-50 2068 (34.9) 25 (41.7) 1.43 (0.73-2.83)  
   51-52 921 (15.5) 7 (11.7) 0.84 (0.32-2.23)  
   53+ 1381 (23.3) 15 (25.0) 1.26 (0.59-2.69) 0.4 
Table continued 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
11 
 
11 
 
Variables 
Number of women without 
SCC (n=10,901) 
N (%)
a
 
Number of women with 
SCC (n=85)  
N (%)
a
 
Adjusted
b
 HR (95%CI) P trend
a
 
MHT use (ever never)      
   No 4150 (65.1) 43 (62.3) 1.00 (Ref)  
   Yes 2229 (34.9) 26 (37.7) 0.79 (0.45-1.38)  
Duration of MHT use (months)      
   0-6 4150 (65.9) 43 (62.3) 1.00 (Ref)  
   7-26 562 (8.9) 10 (14.5) 1.18 (0.52-2.65)  
   27-60 606 (9.6) 6 (8.7) 0.89 (0.38-2.13)  
   61+ 979 (15.6) 10 (14.5) 0.62 (0.27-1.42) 0.6 
MHT use by type of menopause     
Natural menopause - MHT use (ever/never)     
   No 2976 (75.1) 35 (79.6) 1.00 (Ref)  
   Yes 987 (24.9) 9 (20.4) 0.78 (0.43-1.40)  
Hysterectomy – MHT use (ever/never)     
   No 834 (49.5) 7 (36.8) 1.00 (Ref)  
   Yes 852 (50.5) 12 (62.3) 1.02 (0.34-3.04)  
     
a
 Numbers may not sum to total due to missing data; P trend is based on the continuous variable 
b
 Age at menarche adjusted for age at baseline, skin phototype (tanning), freckling on face at age 21, moles at age 21 and smoking status. 
Parity adjusted for age at baseline, skin color, freckling on face at age 21, moles at age 21 and smoking status. 
Menopausal status at baseline adjusted for age at baseline, skin color, freckling on face at age 21, moles at age 21 and smoking status. 
Age at menopause adjusted for age at baseline, skin phototype (tanning) and moles at age 21 and smoking status.  
OC use adjusted for age at baseline, skin color, freckling on face at age 21, moles at age 21, number of sunburns as a child and smoking status. 
MHT use adjusted for age at baseline, eye color, moles at age 21, sunburns as a teenager/youth and smoking status. 
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Supplementary Table I. Distribution of selected characteristics of 11,152 women in the QSkin study cohort, and stratified by MHT use. 
  
  Post-menopausal Women (n=6686)*  
Variables 
All women (n=11,152) MHT use (n=2296)
 
 No MHT use (n=4267)
 
 Chi-Square 
P value N (%)
a
 N (%)
a
 N (%)
a
 
Age at entry (Mean, SD) 53.7 (8.1) 60.7 (5.8) 57.6 (6.1) <0.001
b
 
Age group     
40-49 4137 (37.1) 90 (3.9) 422 (9.9)  
50-59 4180 (37.5) 932 (40.6) 2342 (54.9)  
60-69 2835 (25.4) 1274 (55.5) 1503 (35.2) <0.001 
Further Education     
No school certificate 785 (7.4) 246 (11.5) 382 (9.5)  
School certificate 1792 (17.0) 484 (22.7) 826 (20.5)  
Higher school certificate 2369 (22.4) 459 (21.5) 948 (23.6)  
Trade/certificate/diploma 2749 (26.0) 485 (22.7) 996 (24.8)  
University degree 2873 (27.2) 462 (21.6) 871 (21.7) 0.009 
Skin color     
Fair 6076 (54.8) 1231 (54.2) 2169 (51.2)  
Medium 4184 (37.8) 874 (38.5) 1727 (40.7)  
Olive/dark 819 (7.4) 167 (7.4) 344 (8.1) 0. 1 
Eye color     
Blue 3836 (34.8) 795 (35.1) 1426 (33.9)  
Green 1744 (15.8) 339 (15.0) 659 (15.7)  
Hazel 2805 (25.5) 609 (26.9) 1055 (25.1)  
Brown 2627 (23.9) 523 (23.1) 1061 (25.3) 0.1 
Hair color     
Blonde  1738 (15.7) 329 (14.4) 623 (14.7)  
Red/auburn 457 (4.1) 95 (4.2) 163 (3.8)  
Light brown 4332 (39.1) 874 (38.3) 1659 (39.1)  
Dark brown 4185 (37.7) 883 (38.7) 1624 (38.3)  
Black 382 (3.4) 100 (4.4) 172 (4.1) 0.9 
Skin type     
Skin reaction to 30 minutes midday sun     
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  Post-menopausal Women (n=6686)*  
Variables 
All women (n=11,152) MHT use (n=2296)
 
 No MHT use (n=4267)
 
 Chi-Square 
P value N (%)
a
 N (%)
a
 N (%)
a
 
No burns 1009 (9.1) 283 (12.4) 444 (10.5)  
Burns a little 4934 (44.5) 1055 (46.3) 2026 (47.8)  
Burns moderately 3710 (33.5) 690 (30.3) 1325 (31.2)  
Burns badly 1436 (13.0) 252 (11.1) 446 (10.5) 0.1 
Skin reaction to several weeks in sun     
No tan 529 (4.8) 103 (4.5) 181 (4.3)  
Tan lightly 2145 (19.4) 398 (17.5) 772 (18.2)  
Tan moderately 5757 (51.9) 1206 (53.0) 2237 (52.8)  
Tan deeply 2657 (24.0) 570 (25.0) 1050 (24.8) 0.9 
Freckles at age 21 years (face)     
None 4997 (45.0) 1193 (52.2) 2182 (51.4)  
A few 3750 (33.8) 732 (32.0) 1313 (30.9)  
Some 1774 (16.0) 293 (12.8) 559 (13.6)  
Many 583 (5.3) 67 (2.9) 175 (4.1) 0.1 
Moles at age 21 (whole body)     
None 2588 (23.8) 704 (31.5) 1175 (28.3)  
A few 6241 (57.3) 12257 (54.8) 2342 (56.4)  
Some 1691 (15.5) 278 (12.4) 541 (13.0)  
Many 369 (3.4) 30 (1.3) 97 (2.3) 0.004 
Sunburns as a child     
Never 2804 (27.6) 620 (30.4) 1191 (31.1)  
1-5 4665 (46.0) 948 (46.6) 1758 (45.9)  
6-10 1483 (14.6) 261 (12.8) 499 (13.0)  
11-20 784 (7.7) 138 (6.8) 249 (6.5)  
21-50 276 (2.7) 41 (2.0) 93 (2.4)  
50+ 133 (1.3) 28 (1.4) 44 (1.2) 0.8 
Lifetime sunbed use    
 
Never 9219 (83.1) 1990 (87.2) 3701 (87.2) 
 
1-5 1168 (10.5) 191 (8.4) 348 (8.2) 
 
6-10 302 (2.7) 40 (1.8) 84 (2.0) 
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  Post-menopausal Women (n=6686)*  
Variables 
All women (n=11,152) MHT use (n=2296)
 
 No MHT use (n=4267)
 
 Chi-Square 
P value N (%)
a
 N (%)
a
 N (%)
a
 
11-20 206 (1.9) 34 (1.5) 61 (1.4) 
 
21-50 142 (1.3) 17 (0.8) 34 (0.8)  
50+ 60 (0.5) 8 (0.4) 17 (0.4) 0.98 
Total lifetime sun exposure     
Q1 3634 (37.6) 559 (29.4) 1176 (32.8)  
Q2 6579 (30.5) 525 (27.6) 1047 (29.2)  
Q3 2095 (21.7) 491 (25.8) 898 (25.1)  
Q4 990 (10.2) 328 (17.2) 462 (12.9) <0.001 
Skin checks by a Doctor (past 3 years)     
None 4065 (37.5) 791 (36.0) 1696 (41.3)  
1 3797 (35.1) 756 (34.4) 1375 (33.5)  
2-5 2850 (26.3) 618 (28.1) 985 (24.0)  
6+ 122 (1.1) 31 ( 1.4) 51 ( 1.2) <0.001 
Smoking status at baseline     
Non-Smoker 6573 (59.1) 1273 (55.5) 2511 (59.0)  
Ex-Smoker 3525 (31.7) 845 (36.9) 1307 (30.7)  
Current smoker 1001 (9.2) 175 (7.6) 436 (10.3) <0.001 
a
 Numbers may not sum to total due to missing data *MHT use missing for n=123 women 
b 
P value for significant difference between MHT user and non-users using the Ryan-Einot-Gabriel-Welsch multiple range test 
 
